Can a single gene therapy turn the body into a Cancer-Fighting factory?

NCT ID NCT07735546

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Umoja Biopharma Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 1 trial is testing a new gene therapy called UB-VV500 for people with multiple myeloma that has returned or stopped responding to treatment. The therapy works by giving the body genetic instructions to produce its own CAR T cells that target two proteins on myeloma cells. Participants also receive rapamycin, a drug that may help the engineered cells work better. The study aims to find the safest dose and see whether this approach can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a gene therapy called UB-VV500 that instructs the body to make its own CAR T cells targeting two myeloma proteins, plus the drug rapamycin
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial, so safety and effectiveness are not yet known. Gene therapies can cause serious side effects, and the approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM) MULTIPLE MYELOMA IN RELAPSE

More trials for these conditions

Other studies related to the condition(s) this trial covers.